What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?
Written by Robert Izquierdo for The Motley Fool -> CEO Claire Mazumdar sold 15,000 shares for a transaction value of approximately ~$301,000, based on a weighted average price of around $20.04 per share on May 18, 2026. This represented 3.98% of Mazumdar's direct holdings prior
CEO Claire Mazumdar sold 15,000 shares for a transaction value of approximately ~$301,000, based on a weighted average price of around $20.04 per share on May 18, 2026.
This represented 3.98% of Mazumdar's direct holdings prior to the transaction, with post-transaction direct ownership at 362,152 shares.
The transaction involved exercising 15,000 options and immediately selling the shares; all holdings remain in direct ownership.
Claire Mazumdar, Chief Executive Officer of Bicara Therapeutics Inc. (NASDAQ:BCAX) , reported the exercise of 15,000 stock options with immediate sale of the resulting common shares on May 18, 2026, as disclosed in the SEC Form 4 filing .
Transaction value based on SEC Form 4 weighted average reported price ($20.04); post-transaction value based on May 18, 2026 market close.
* 1-year performance calculated using May 18th, 2026 as the reference date.
Bicara Therapeutics Inc. is a Boston-based clinical-stage biotechnology company specializing in innovative bifunctional therapies for oncology indications. The company's strategic focus on combining targeted antibodies with immunomodulatory domains positions it to address unmet needs in solid tumor treatment.
The May 18 sale of Bicara Therapeutics stock by CEO Claire Mazumdar was a non-discretionary transaction. It was part of a pre-arranged Rule 10b5-1 trading plan, adopted in February of 2025. Such plans are often implemented by insiders to avoid accusations of trading based on insider information.
